Clinical trials: Alopecia Areata
Alopecia Areata
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.
- Trial name
- BRAVE-AA1 (NCT03570749)
- Testing
- Baricitinib
- Where
- 75 sites in United States, Japan and 3 more
- Volunteers
- 784 people
- Sponsor
- Eli Lilly and Company
Female Pattern Hair Loss, Androgenic Alopecia
Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
The purpose of this study is to characterize the effect of Minoxidil 2% Solution and Botanical Hair Solution Regimen in women with thinning hair and female pattern hair loss/androgenic alopecia (Ludwig I and II).
- Trial name
- NCT02460497
- Testing
- Treatment: Minoxidil 2% / Botanical Hair Solution for Women
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Galderma R&D
Androgenetic Alopecia
Computer-Assisted Versus Manual Hair Harvest Comparative Study
The objective of this clinical study is to investigate and compare the safety and efficacy of the Restoration Robotics Computer-Assisted Harvesting System to the manual hair follicle harvesting method following a nine-month…
- Trial name
- NCT00926211
- Testing
- ARTAS™ System, Manual Hair Harvest
- Where
- 2 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Restoration Robotics, Inc.
Alopecia Areata
Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata
The investigators hypothesize that Restylane® could serve as a repair matrix which also maintains IL triamcinolone acetonide concentrations at higher levels for a longer period of time in the skin, giving a more sustained local…
- Trial name
- NCT01797432
- Testing
- Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10), Restylane
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Alopecia Areata
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at…
- Trial name
- NCT05368103
- Testing
- Daxdilimab
- Where
- 13 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Amgen
Frontal Fibrosing Alopecia, Lichen Planopilaris of Scalp
Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
This study aims to determine the efficacy and safety of tofacitinib therapy in Thai patients with recalcitrant frontal fibrosing alopecia. The main questions are 1.
- Trial name
- Tofacitinib (NCT06202560)
- Testing
- Tofacitinib 5 MG
- Where
- Thailand
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Institute of Dermatology, Thailand
Androgenetic Alopecia
Modulated Light Therapy in Participants With Pattern Hair Loss
The REVIAN study is designed as a prospective, randomized, controlled, double-blind, parallel study to evaluate the efficacy and safety of the REVIAN System in male participants with androgenic alopecia.
- Trial name
- REV-01 (NCT04019795)
- Testing
- REVIAN 101, REVIAN 102, REVIAN 103
- Where
- 4 sites in Australia
- Volunteers
- 160 people
- Sponsor
- PhotonMD, Inc
Alopecia, Alopecia, Androgenetic
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia.
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01325337
- Testing
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Where
- 2 sites in United States, Germany
- Volunteers
- 307 people
- Sponsor
- Allergan
Alopecia Universalis (AU), Alopecia Totalis (AT)
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
The primary objective is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution compared to vehicle in subjects with AU and AT.
- Trial name
- NCT03315689
- Testing
- Vehicle, ATI-50002
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia Areata, Alopecia Universalis
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT…
- Conditions
- Alopecia Areata, Alopecia Universalis, Alopecia Totalis
- Trial name
- NCT03759340
- Testing
- ATI 502 0.46% Topical Solution
- Where
- 20 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aclaris Therapeutics, Inc.
Eyelash Hypotrichosis, Alopecia Areata
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough…
- Trial name
- NCT01023841
- Testing
- bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
- Where
- 2 sites in United States, Brazil
- Volunteers
- 71 people
- Sponsor
- Allergan
Androgenetic Alopecia, Alopecia
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
The purpose of this study is to evaluate the clinical efficacy of platelet rich plasma (PRP) injections for non-scaring alopecia in women.
- Trial name
- NCT03689452
- Testing
- Platelet Rich Plasma, Normal saline
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alopecia Areata
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03941548
- Testing
- CTP-543
- Where
- 12 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Concert Pharmaceuticals
Alopecia, Androgenetic
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
The primary objective of this study is to evaluate the safety and feasibility of the Celution and Puregraft Systems in the processing and preparation of an autologous fat graft enriched with adipose-derived regenerative cells…
- Trial name
- STYLE (NCT02503852)
- Testing
- Puregraft System, Celution System, Kerastem Therapy
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- Kerastem Technologies, LLC
Alopecia
Hair Loss Prevention Study for Pancreatic Cancer
Pilot study intended for hair loss prevention in patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin.
- Trial name
- NCT04492800
- Testing
- Paxman Scalp Cooling Device
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- HonorHealth Research Institute
Alopecia
Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women
The primary objective of this proposal is to conduct a study that assesses the safety, feasibility and efficacy of using PRP to treat this type of hair loss.
- Trial name
- NCT03488108
- Testing
- Platelet Rich Plasma, Minoxidil Foam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Alopecia Areata
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.
- Trial name
- NCT05556265
- Testing
- Deucravacitinib
- Where
- 28 sites in United States, Australia and 4 more
- Volunteers
- 94 people
- Sponsor
- Bristol-Myers Squibb
Alopecia Areata
Long-Term PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata.
- Trial name
- ALLEGRO-LT (NCT04006457)
- Testing
- PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 1,057 people
- Sponsor
- Pfizer
Alopecia Areata
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03811912
- Testing
- CTP-543
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Concert Pharmaceuticals
Androgenetic Alopecia, Hair Loss
Treatment of Androgenic Alopecia in Males
The purpose of this study is to evaluate the change in terminal hair count at 16 and 26 weeks compared to baseline measurements.
- Conditions
- Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
- Trial name
- NCT00947219
- Testing
- HairMax LaserComb, Control device
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC